Loading…
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $41M | $-149M | $-160M | $-166M | -586.6% | 25.4% | -32.5% |
| 2024 | $32M | $-229M | $-237M | $-219M | -176.6% | -58.6% | 54.7% |
| 2023 | $78M | $-163M | $-153M | $-137M | -43.9% | 296.3% | -30.5% |
| 2022 | $20M | $-220M | $-220M | $-181M | -61.1% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 19.71 | 78.12 | 32.31 | 40.52 |
| Operating Revenue | - | 19.71 | 78.12 | 32.31 | 40.52 |
| Operating Expense | - | 245.66 | 247.30 | 271.23 | 139.86 |
| Research And Development | - | 174.96 | 177.65 | 199.25 | 89.95 |
| Selling General And Administration | - | 70.70 | 69.65 | 71.99 | 49.90 |
| Total Expenses | - | 245.66 | 247.30 | 271.23 | 139.86 |
| Operating Income | - | -225.95 | -169.18 | -238.92 | -99.34 |
| Total Operating Income As Reported | - | -225.95 | -169.18 | -251.15 | -160.01 |
| EBITDA | - | -219.61 | -163.12 | -229.09 | -148.61 |
| Normalized EBITDA | - | -219.61 | -163.12 | -216.86 | -87.94 |
| EBIT | - | -225.95 | -169.18 | -234.90 | -153.89 |
| Interest Income | - | 5.52 | 17.57 | 16.25 | 8.31 |
| Interest Expense | - | - | - | 2.19 | 6.17 |
| Net Interest Income | - | 5.52 | 17.57 | 14.06 | 2.14 |
| Other Non Operating Income Expenses | - | 1.29 | -1.60 | 0 | -2.19 |
| Other Income Expense | - | 1.29 | -1.60 | -12.24 | -62.86 |
| Interest Income Non Operating | - | 5.52 | 17.57 | 16.25 | 8.31 |
| Interest Expense Non Operating | - | - | - | 2.19 | 6.17 |
| Net Non Operating Interest Income Expense | - | 5.52 | 17.57 | 14.06 | 2.14 |
| Pretax Income | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income From Continuing And Discontinued Operation | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income From Continuing Operation Net Minority Interest | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income Common Stockholders | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income Including Noncontrolling Interests | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Normalized Income | - | -220.43 | -153.22 | -224.86 | -99.39 |
| Diluted NI Availto Com Stockholders | - | -220.43 | -153.22 | -237.09 | -160.06 |
| Basic Average Shares | 67.62 | 68.66 | 75.97 | 82.34 | - |
| Diluted Average Shares | 67.62 | 68.66 | 75.97 | 82.34 | - |
| Reconciled Depreciation | - | 6.34 | 6.06 | 5.81 | 5.28 |
| Total Unusual Items | - | 0 | 0 | -12.23 | -60.67 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | -12.23 | -60.67 |
| Special Income Charges | - | 0 | 0 | -12.23 | -60.67 |
| Restructuring And Mergern Acquisition | - | 0 | 0 | 12.23 | 60.67 |
| General And Administrative Expense | - | 70.70 | 69.65 | 71.99 | 49.90 |
| Other Gand A | - | 70.70 | 42.73 | 38.45 | 30.66 |
| Salaries And Wages | - | 34.19 | 26.92 | 33.54 | 19.24 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Editas Medicine, Inc.this co. | EDIT | $459M | -2.87 | 16.82 | -586.6% | -2.22 |
| The Oncology Institute, Inc. | TOI | $474M | -7.82 | -30.15 | 385.5% | -12.80 |
| CTEV | CTEV | $470M | - | - | 163.5% | 10.85 |
| OrthoPediatrics Corp. | KIDS | $465M | -11.73 | 1.34 | -11.4% | -69.20 |
| Weave Communications, Inc. | WEAV | $459M | -16.37 |
| - |
| - |
| - |
| - |
| - |
| - |
| 5.57 |
| -34.1% |
| -42.33 |
| NRC Health | NRC | $445M | 38.37 | 31.82 | 82.9% | 17.20 |
| Myriad Genetics, Inc. | MYGN | $443M | -1.21 | 1.20 | -99.4% | -1.52 |
| Varex Imaging Corporation | VREX | $441M | - | 0.93 | -14.9% | 973.79 |
| Emergent BioSolutions Inc. | EBS | $435M | 8.28 | 0.83 | 10.1% | 3.37 |
| Peer Median | - | -4.52 | 1.20 | -0.7% | 0.93 | |